Vaxcyte, Inc. (PCVX)
61.16
+0.06
(+0.11%)
USD |
NASDAQ |
Aug 27, 16:00
61.18
+0.02
(+0.04%)
After-Hours: 20:00
Vaxcyte Shareholders Equity (Quarterly) : 2.758B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.758B |
| March 31, 2026 | 2.996B |
| December 31, 2025 | 2.686B |
| September 30, 2025 | 2.893B |
| June 30, 2025 | 3.071B |
| March 31, 2025 | 3.200B |
| December 31, 2024 | 3.306B |
| September 30, 2024 | 3.418B |
| June 30, 2024 | 1.986B |
| March 31, 2024 | 1.984B |
| December 31, 2023 | 1.240B |
| September 30, 2023 | 1.403B |
| June 30, 2023 | 1.433B |
| March 31, 2023 | 944.77M |
| Date | Value |
|---|---|
| December 31, 2022 | 953.61M |
| September 30, 2022 | 359.31M |
| June 30, 2022 | 366.50M |
| March 31, 2022 | 359.54M |
| December 31, 2021 | 284.02M |
| September 30, 2021 | 305.96M |
| June 30, 2021 | 317.02M |
| March 31, 2021 | 326.94M |
| December 31, 2020 | 345.84M |
| September 30, 2020 | 364.08M |
| June 30, 2020 | 383.21M |
| March 31, 2020 | 137.22M |
| December 31, 2019 | 53.94M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Moderna, Inc. | 6.761B |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 3.138B |
| Total Liabilities (Quarterly) | 380.21M |
| Debt to Equity Ratio | 0.0419 |
| Current Ratio | 5.724 |
| Net Debt Paydown Yield | -0.07% |